WebApr 11, 2024 · Ironwood Pharmaceuticals is a publicly-traded pharmaceutical company based in Massachusetts. After nearly a decade in development, in Q3 2012 the company launched its first product, LINZESS®, a breakthrough therapy for irritable bowel syndrome with constipation (IBS-C). The product was co-developed and co-commercialized in a 50 … WebLINZESS is contraindicated in patients less than 2 years of age due to the risk of serious dehydration. LINZESS is contraindicated in patients with known or suspected mechanical gastrointestinal obstruction. Warnings and Precautions Risk of Serious Dehydration in Pediatric Patients Less Than 2 Years of Age
OTC and Prescription Treatments LINZESS (linaclotide)
WebLINZESS® (linaclotide) is a prescription medication used in adults to treat irritable bowel syndrome with constipation (IBS‑C) and chronic idiopathic constipation (CIC). "Idiopathic" means the cause of the constipation is unknown. It is not known if LINZESS is safe and effective in children less than 18 years of age. IMPORTANT RISK INFORMATION WebApr 1, 2024 · In the United States, Ironwood and Allergan plc co-develop and co-commercialize LINZESS for the treatment of adults with IBS-C or CIC. In Europe, Allergan markets linaclotide under the brand... flare bushing
Ironwood Pharmaceuticals Announces FDA Approval of …
WebFeb 13, 2024 · Ironwood Pharmaceuticals, Inc. (Nasdaq: IRWD), a GI-focused healthcare company, today announced that the U.S. Food and Drug Administration (FDA) has granted Priority Review to the supplemental New Drug Application (sNDA) for LINZESS ® (linaclotide) for the treatment of children and adolescents ages 6-17 years-old with … WebIronwood Pharmaceuticals. University of Massachusetts Amherst. ... • Authored and managed updates to core LINZESS documents such as Company Core Safety Information (CCSI), Risk Minimization Plan ... WebLINZESS is a peptide that stimulates the guanylate cyclase (GC-C) receptor and is thought to work in 2 ways* cGMP, cyclic guanosine monophosphate; GI, gastrointestinal. *Based on nonclinical studies. † The clinical relevance of the effect on … can someone see i took a screenshot